Jennerex

Targeting, Attacking, and Eradicating Cancers®

Jennerex, Inc.

◀ MOA video

▲ MOA video

SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics. Jennerex was an early leader in the oncolytic virus field.Jennerex researchers showed that Pexa-Vec acts in three distinct ways to attackcancer: by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer.

Scientific Publications 01

Jennerex scientists were the first to show that IV infusion could be used to deliver oncolytic vaccinia to tumors. The key paper “Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans” showed thatIV delivery of Pexa-Vec (JX-594) resulted in viral infection, viral replication and expression of a transgene marker protein in tumors in a dose dependent fashion, while healthy cells were not infected.

Further work demonstrated that Pexa-Vec was able to infect the blood vessels associated with tumors, creating leaky blood vessels and disrupting the blood flow to tumors. Normal blood vessels were not affected.

Finally, the Jennerex sponsored phase 2 trial in Hepatocellular carcinoma paved the way for SillJen’s Phase 3 PHOCUS trial. In this dose-finding trial, patients received either a low dose or high dose of virus injected into liver tumors. Patients who received the high dose of virus had a significantly longer median overall survival time compared to the low dose group.